PPAR𝜹 Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities

Table 1

Compounds with similar in vitro profiles induced different in vivo efficacy.

Compound	In vitro potentcy (μM)			Weight loss	Insulin (% reduction)	Adiponectin (fold increase)
	α	γ	δ
1 [69, 70]	6.0	0.1	5.0	Weight neutral	30%	2.1
2 [69, 70]	3.0	0.1	1.0	14%	80%	3.2